Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761384 | 1.00 | CA12 (0.36) | CA12CA14AAK1CXCR2CXCR1 | |
| SCHEMBL1923604 | 1.00 | CA12 (0.36) | CA12CA14AAK1CXCR2CXCR1 | |
| SCHEMBL5551942 | 0.82 | CA12 (0.34) | CA12CA14AAK1CXCR2 | |
| SCHEMBL31153798 | 0.82 | CA12 (0.34) | CA12CA14AAK1CXCR2 | |
| SCHEMBL1923926 | 0.82 | CA2 (0.38) | CA12CA14 | |
| SCHEMBL3770785 | 0.82 | CA2 (0.38) | CA12CA14 | |
| SCHEMBL16584183 | 0.81 | CA14 (0.41) | CA12CA14CXCR2CXCR1 | |
| SCHEMBL2598240 | 0.81 | CA14 (0.41) | CA12CA14CXCR2CXCR1 | |
| SCHEMBL2797628 | 0.81 | CA14 (0.41) | CA12CA14CXCR2CXCR1 | |
| SCHEMBL10890446 | 0.79 | ALDH1A1 (0.41) | CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4691049-A | Process for preparing a specific diastereomer of a monoamino dicarboxylic acid ester | SCHERING CORPORATION (US) | 1987-09-01 | — | — | US | claimed |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-7576098-B2 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2008144728-A1 | CONJUGATES WHICH BIND A BLOOD PROTEIN SUCH AS HUMAN SERUM ALBUMIN AND METHODS OF USING THE SAME IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2008-11-27 | — | — | WO | disclosed |
| EP-1828152-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL MYERS SQUIBB CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-5017567-A | Steroid antiinflammatory | SCHERING CORPORATION (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0236307-B1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4906635-A | Carboxyalkyl dipeptides as antiglaucoma agents | SCHERING CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4840772-A | KIT WITH CONTAINERS OF AGENT TO REDUCE INTRAOCULAR PRESSURE AND ANTIINFLAMMATORY STEROID OR BETA-BLOCKER | SCHERING CORPORATION (US) | 1989-06-20 | — | — | US | disclosed |
| US-4783444-A | SUBSTITUTED DIPEPTIDES | SCHERING CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| US-4778795-A | Carboxyalkyl dipeptides as antiglaucoma agents | SCHERING CORPORATION (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0236307-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS. | SCHERING CORP (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4691049-A | Process for preparing a specific diastereomer of a monoamino dicarboxylic acid ester | SCHERING CORPORATION (US) | 1987-09-01 | — | — | US | disclosed |
| WO-1987001707-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1987-03-26 | — | — | WO | disclosed |
| US-4616012-A | BENZOTHIADIZINYL AND QUINAZOLINYL DERIVATIVES | SCHERING CORPORATION (US) | 1986-10-07 | — | — | US | disclosed |
| US-4584285-A | Antihypertensive agents | SCHERING CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
| US-4559340-A | DIURETICS; GLAUCOMA | SCHERING CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | TFPI, F7, HABP2 | CA12 1385/4885CA14 779/4885AAK1 1763/4885 |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | CA12 1326/4885CA14 1937/4885AAK1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.